Literature DB >> 31892283

Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib.

Laura Leroy1, Benjamin Bonhomme1, Sylvestre Le Moulec1, Isabelle Soubeyran1, Antoine Italiano1,2, Yann Godbert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31892283     DOI： 10.1089/thy.2019.0202

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  9 in total

1.  Kinase fusion-related thyroid carcinomas: distinct pathologic entities with evolving diagnostic implications.

Authors:  Ying-Hsia Chu; Peter M Sadow
Journal:  Diagn Histopathol (Oxf)       Date:  2021-03-31

Review 2.  Predictive Biomarkers in Thyroid Cancer.

Authors:  Elisabetta Macerola; Anello Marcello Poma; Paola Vignali; Agnese Proietti; Clara Ugolini; Liborio Torregrossa; Alessio Basolo; Rossella Elisei; Ferruccio Santini; Fulvio Basolo
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

Review 3.  Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.

Authors:  Ichiro Abe; Alfred King-Yin Lam
Journal:  Curr Oncol Rep       Date:  2021-02-13       Impact factor: 5.075

Review 4.  American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Authors:  David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph
Journal:  Head Neck       Date:  2022-03-11       Impact factor: 3.821

Review 5.  Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.

Authors:  María San Román Gil; Javier Pozas; Javier Molina-Cerrillo; Joaquín Gómez; Héctor Pian; Miguel Pozas; Alfredo Carrato; Enrique Grande; Teresa Alonso-Gordoa
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

6.  A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report.

Authors:  Lin Gui; Shaoyan Liu; Ye Zhang; Yuankai Shi
Journal:  Onco Targets Ther       Date:  2021-04-20       Impact factor: 4.147

7.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

Review 8.  Molecular-Driven Therapy in Advanced Thyroid Cancer.

Authors:  Kevin C Miller; Ashish V Chintakuntlawar
Journal:  Curr Treat Options Oncol       Date:  2021-02-10

Review 9.  Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.

Authors:  Tanner Fullmer; Maria E Cabanillas; Mark Zafereo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-15       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.